Pancragen
Evidence: CExperimental / Early Research
Evidence Snapshot
Regulatory Context
Do not describe Pancragen as an approved diabetes, pancreatitis, or pancreatic-restoration treatment.
Research Takeaway
Pancragen is described in the indexed bioregulator literature as the KEDW tetrapeptide Lys-Glu-Asp-Trp.
See all 6 evidence claims →Quick Summary
Pancragen is a short peptide bioregulator described in the indexed literature as the tetrapeptide Lys-Glu-Asp-Trp (KEDW). It has been studied mainly in pancreatic cell, animal, and non-human-primate metabolic models.
Mechanism & Research Overview
Cell studies report modulation of pancreatic differentiation markers including PDX1 and other transcription factors associated with acinar/islet differentiation.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Pancragen is described in the indexed bioregulator literature as the KEDW tetrapeptide Lys-Glu-Asp-Trp.
Sources: Effect of Pancragen on blood glucose, capillary permeability and adhesion
Supported
Cell studies report modulation of pancreatic differentiation markers including PDX1 and other transcription factors associated with acinar/islet differentiation.
Supported
Animal and non-human-primate studies report changes in glucose/insulin-related measures.
Sources: Effect of Pancragen on blood glucose, capillary permeability and adhesion; Non-human primate endocrine-pancreatic study of Pancragen; Impaired glucose tolerance in old monkeys: Pancragen and glimepiride comparison
Supported
Limited human metabolic reports exist, but they do not establish Pancragen as a modern evidence-based diabetes therapy.
Sources: Metabolic-disorder / type-2 diabetes report involving Pancragen
Supported
Effects in pancreatic cell cultures or aging primates do not establish prevention or reversal of diabetes in humans.
Sources: Pancragen pancreatic-cell differentiation study; Impaired glucose tolerance in old monkeys: Pancragen and glimepiride comparison
Supported
Do not describe Pancragen as an approved diabetes, pancreatitis, or pancreatic-restoration treatment.
Sources: MitoCore Batch 9 regulatory search: FDA approval status and ClinicalTrials.gov registration check
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Limited human metabolic reports exist but do not establish Pancragen as a modern evidence-based diabetes therapy.Safety Consideration
Much of the Pancragen evidence originates from the Khavinson research program, limiting independent replication.Safety Consideration
A substantial portion of the Pancragen literature comes from overlapping investigators and institutions within the Khavinson/St. Petersburg bioregulator research program. This concentration limits independent replication and generalizability; repeated publications from the same research lineage should not be interpreted as equivalent to independent multicenter replication.
Research Areas Being Studied
Research areas discussed on this page reflect the Experimental / Early Research category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Metabolic-disorder / type-2 diabetes report involving Pancragen ():
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Metabolic-disorder / type-2 diabetes report involving Pancragen | Limited report discussing Pancragen in the context of metabolic disorder / type-2 diabetes; does not establish a modern evidence-based diabetes therapy. |
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Effect of Pancragen on blood glucose, capillary permeability and adhesion | Reported changes in blood glucose and capillary permeability/adhesion measures associated with Pancragen administration. | ||||
| Impaired glucose tolerance in old monkeys: Pancragen and glimepiride comparison | Aging-monkey model comparing Pancragen with the drug glimepiride on glucose-tolerance measures. | ||||
| Non-human primate endocrine-pancreatic study of Pancragen | Non-human primate study reporting endocrine-pancreatic measures associated with Pancragen. | ||||
| Pancragen pancreatic-cell differentiation study | Cell studies report modulation of pancreatic differentiation markers, including PDX1 and other transcription factors associated with acinar/islet differentiation. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| MitoCore Batch 9 regulatory search: FDA approval status and ClinicalTrials.gov registration check | 2026 | Direct search performed 2026-08-17 for FDA drug-approval status and ClinicalTrials.gov interventional-trial registration for PNC-27, Pancragen, Bronchogen, Testagen, Chonluten, Prostamax, Ovagen, and N-Acetyl Epitalon Amidate (Ac-AEDG-NH2), including known aliases and sequence names. No FDA-approved drug product was identified for any of the eight compounds. No registered ClinicalTrials.gov interventional trial was identified for any of the eight compounds. All eight are marketed exclusively through peptide/research-chemical vendors as research-use-only products, not as approved medicines. Absence from these searches is not itself a formal FDA determination and does not establish safety or ineffectiveness -- it establishes only that no approval or registered trial was located in this search pass. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Extracellular-matrix-derived peptide paper discussing KEDW/Pancragen-associated pancreatic marker expression | Discusses KEDW/Pancragen-associated pancreatic marker expression in the context of extracellular-matrix-derived peptides. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Content pending review. Last updated 2026-08-17.
Follow research updates for Pancragen
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.